|
1) Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006; 7: 306-18
|
|
|
|
2) Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinsonʼs disease. Nat Genet. 2009: 41: 1303-7
|
|
|
|
|
|
3) Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinsonʼs disease in Iceland. N Engl J Med. 2000; 343: 1765-70
|
|
|
|
|
|
4) Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet. 2006; 15: 1151-8
|
|
|
|
|
|
5) Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinsonʼs disease. Ann Neurol. 2005; 57: 535-41
|
|
|
|
|
|
6) International HapMap Consortium. A second generation human haplotype map of over 3. 1 million SNPs. Nature. 2007; 449: 851-61
|
|
|
|
|
|
7) Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005; 77: 685-93
|
|
|
|
|
|
8) Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinsonʼs disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006; 5: 911-6
|
|
|
|
|
|
9) Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009; 72: 593-605
|
|
|
|
|
|
10) Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinsonʼs disease. Nat Genet. 2009; 41: 1308-12
|
|
|
|
|
|
11) Ostvold AC, Norum JH, Mathiesen S, et al. Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem. 2001; 268: 2430-40
|
|
|
|
|
|
12) Yamamoto-Katayama S, Ariyoshi M, Ishihara K, et al. Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. J Mol Biol. 2002; 316: 711-23
|
|
|
|
|
|
13) Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinsonʼs disease. Lancet Neurol. 2007; 6: 933-8
|
|
|
|
|
|
14) Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinsonʼs disease. Nat Genet. 2010; 42: 781-5
|
|
|
|
|
|
15) Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinsonʼs disease in Ashkenazi Jews. N Engl J Med. 2004; 351: 1972-7
|
|
|
|
|
|
16) Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol. 2009; 66: 571-6
|
|
|
|
|
|
17) Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinsonʼs disease. N Engl J Med. 2009; 361: 1651-61
|
|
|
|
|
|
18) Ng SB, Bigham AW, Buckingham KJ, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010; 42: 790-3
|
|
|
|
|